Solid Biosciences' Presentation at the MDA Conference
Solid Biosciences Inc. (NASDAQ: SLDB), a pioneering life sciences company dedicated to creating precision genetic medicines for neuromuscular and cardiac diseases, is gearing up to present pivotal data from their innovative Phase 1/2 INSPIRE DUCHENNE trial. This trial assesses SGT-003, a next-generation gene therapy candidate aimed at treating Duchenne muscular dystrophy (Duchenne). The presentation is scheduled for the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, a notable event slated to take place in Texas.
Oral Presentation Highlights
Details of the Presentation
The oral presentation will focus on the insights gained from the INSPIRE DUCHENNE trial. Key information includes:
- Title: Initial Experience from the INSPIRE DUCHENNE Phase I/II Study of SGT-003 Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy
- Location: Coronado ABCD
- Date and Time: March 19, 2025; 1:45 - 2:00 PM CT
- Presenter: Dr. Kevin Flanigan, a renowned advisor and researcher from Nationwide Children's Hospital.
Understanding Duchenne Muscular Dystrophy
Duchenne muscular dystrophy is a severe genetic disorder that primarily affects boys. Symptoms generally manifest between the ages of three and five, leading to progressive muscle weakness and eventual loss of mobility. Affecting approximately one in every 3,500 to 5,000 male births globally, Duchenne presents a significant challenge given its fatal progression if left untreated.
The Innovative Approach of SGT-003
SGT-003 stands out as a groundbreaking investigational gene therapy that incorporates a unique microdystrophin construct. It utilizes a proprietary next-generation AAV capsid, AAV-SLB101, engineered specifically to improve delivery to muscle tissues. Preclinical studies of SGT-003 have indicated promising outcomes, particularly in minimizing liver targeting while enhancing cardiac and skeletal muscle transduction.
Mechanism of Action
SGT-003's microdystrophin design boasts R16/17 domains, which have demonstrated potential in localizing neuronal nitric oxide synthase (nNOS) to muscle tissues. In early studies, nNOS has been linked to improved blood circulation to muscles, thereby countering muscle fatigue and damage, making SGT-003 a beacon of hope in the landscape of Duchenne treatments.
About the INSPIRE DUCHENNE Trial
INSPIRE DUCHENNE is a first-of-its-kind, open-label, multicenter clinical study that is set to evaluate both the safety and efficacy of SGT-003. This trial aims to enroll pediatric patients who possess a documented dystrophin gene mutation, with sites across multiple countries to maximize participant diversity.
Solid Biosciences: A Focused Mission
Solid Biosciences is devoted to advancing genetic medicine for rare neuromuscular and cardiac diseases, striving to develop groundbreaking therapies that could transform lives. The company’s mission is deeply rooted in patient care, having been founded by individuals with direct connections to Duchenne muscular dystrophy, which fuels their resolve to deliver innovative solutions to rare disease challenges.
Innovative Therapies
Beyond Duchenne, Solid is investigating treatments for Friedreich's ataxia and various other genetic cardiac diseases. This broad mission encompasses a dedication to cutting-edge genetic regulatory techniques to enhance the delivery and efficacy of gene therapies.
Contact Information
If you are looking for more information regarding Solid Biosciences and their compelling advancements, please reach out to:
Investor Relations:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
Email: investors@solidbio.com
Media Inquiries:
Glenn Silver
FINN Partners
Email: glenn.silver@finnpartners.com
Frequently Asked Questions
What is the purpose of the INSPIRE DUCHENNE trial?
The INSPIRE DUCHENNE trial aims to evaluate the safety and efficacy of the gene therapy candidate SGT-003 in treating Duchenne muscular dystrophy.
Who is presenting the data at the MDA Conference?
Dr. Kevin Flanigan, a noted researcher and advisor from Nationwide Children's Hospital, will present the data.
What is SGT-003?
SGT-003 is an investigational gene therapy designed to treat Duchenne muscular dystrophy using a unique microdystrophin construct and innovative delivery methods.
How does Duchenne muscular dystrophy affect patients?
Duchenne is a genetic disorder that leads to progressive muscle degeneration, primarily affecting boys, often resulting in severe disability and early mortality.
What differentiates Solid Biosciences from other companies?
Solid Biosciences' mission is driven by personal experiences related to Duchenne, fostering a deep commitment to improving patient outcomes through innovative therapies.
